Core Viewpoint - S&P Global (SPGI) has experienced a significant decline of 13.4% over the past four weeks, but it is now in oversold territory, indicating a potential for a trend reversal as analysts expect better earnings than previously predicted [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2]. - SPGI's current RSI reading is 23.41, suggesting that the heavy selling pressure may be exhausting itself and a trend reversal could occur soon [5]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that SPGI's earnings estimates for the current year have increased by 0.8% over the last 30 days, which usually correlates with price appreciation [7]. - SPGI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a potential turnaround [8].

Core Viewpoint - Gilead Sciences, Inc. (GILD) is set to report its fourth-quarter and full-year 2025 results on February 10, with consensus estimates for sales at $7.57 billion and earnings per share (EPS) at $1.83 [1][5] Financial Estimates - The earnings estimate for 2025 has decreased to $8.13 from $8.18 per share over the past 60 days, while the estimate for 2026 has increased to $8.60 from $8.56 [1] - The current earnings estimates for Q1 and Q2 are $1.83 and $1.90, respectively, with a trend showing a decrease of 3.17% for Q1 and an increase of 2.70% for Q2 over the past 60 days [2] Earnings Performance - GILD has a strong earnings surprise history, beating estimates in three of the last four quarters with an average surprise of 7.80%, including a 14.88% beat in the last reported quarter [2][3] Product Performance - Gilead's HIV franchise, particularly Biktarvy and Descovy, remains the primary growth driver, with Biktarvy accounting for over 52% of the U.S. treatment market [5][8] - The estimated sales for Biktarvy and Descovy are $3.8 billion and $703 million, respectively, with Yeztugo contributing $39 million in the third quarter [9][10] - The liver disease portfolio has seen increased sales, particularly for Livdelzi, while cell therapy sales are expected to decline due to competitive pressures [12][13] Market Position and Valuation - GILD's shares have increased by 49.2% over the past year, outperforming the industry growth of 31% [15] - The current price/earnings ratio for GILD is 16.85x forward earnings, higher than its historical mean of 11.17x but lower than the large-cap pharma industry average of 18.13x [18] Strategic Initiatives - Gilead is focusing on innovation within its HIV portfolio and has received positive data from phase III studies for new treatments [19][20] - The company is also pursuing strategic collaborations, including partnerships with Merck to enhance its product offerings [25]

Core Viewpoint - Popular (BPOP) has shown strong stock performance, with a 9.6% increase over the past month and a 13.6% gain since the beginning of the year, outperforming the Zacks Finance sector and the Zacks Banks - Southeast industry [1] Company Performance - Popular has consistently exceeded earnings expectations, reporting an EPS of $3.38 against a consensus estimate of $3.02 in its last earnings report [2] - The stock has reached a new 52-week high of $145.34, raising questions about its future performance and valuation metrics [1][3] Valuation Metrics - Popular's current trading metrics include a P/E ratio of 9.9X for the current fiscal year EPS estimates, below the peer industry average of 11.2X, and a trailing cash flow basis P/E of 22.3X compared to the peer average of 12.6X [6] - The stock has a PEG ratio of 0.88, positioning it favorably among value investors [6] Zacks Rank and Style Scores - Popular holds a Zacks Rank of 2 (Buy) due to a positive earnings estimate revision trend, indicating potential for further stock price appreciation [7] - The stock has a Value Score of A, a Growth Score of D, and a Momentum Score of A, resulting in a combined VGM Score of B [5][7] Industry Comparison - The Banks - Southeast industry is performing well, ranking in the top 16% of all industries, providing a favorable environment for both Popular and its peers [10] - Hilltop Holdings Inc. (HTH), a competitor, has a Zacks Rank of 1 (Strong Buy) and has also shown strong earnings performance, beating consensus estimates by 50% [8][9]

Core Viewpoint - Fifth Third Bancorp (FITB) has shown strong stock performance, with a 10% increase over the past month and a new 52-week high of $55.36, outperforming the Zacks Finance sector and the Zacks Banks - Major Regional industry [1] Financial Performance - The company has consistently exceeded earnings expectations, reporting an EPS of $1.08 against a consensus estimate of $1.01 in its last earnings report [2] - For the current fiscal year, Fifth Third Bancorp is projected to achieve earnings of $4.04 per share on revenues of $9.43 billion, reflecting an 11.29% increase in EPS and a 4.53% increase in revenues [3] - The forecast for the next fiscal year indicates earnings of $4.87 per share on revenues of $10.02 billion, representing a year-over-year change of 20.54% in EPS and 6.26% in revenues [3] Valuation Metrics - The stock trades at 13.4 times the current fiscal year EPS estimates, which is above the peer industry average of 12.7 times [7] - On a trailing cash flow basis, the stock is valued at 12.2 times, matching the peer group's average [7] - The PEG ratio stands at 1.09, indicating that the company is not among the top tier in terms of value [7] Zacks Rank and Style Scores - Fifth Third Bancorp holds a Zacks Rank of 2 (Buy), supported by favorable earnings estimate revisions from analysts [8] - The company has a Value Score of B, with Growth and Momentum Scores both at C, resulting in a combined VGM Score of B [6] - The alignment with Zacks Rank recommendations suggests that Fifth Third Bancorp shares may continue to experience gains [9]

Core Viewpoint - First Financial Corp. (THFF) has shown strong stock performance, with a 12.1% increase over the past month and reaching a new 52-week high of $69.21, outperforming the Zacks Finance sector and the Zacks Banks - Midwest industry [1]. Performance Summary - The stock has consistently beaten earnings estimates, reporting an EPS of $1.81 against a consensus estimate of $1.69 in its last earnings report [2]. - Year-to-date, First Financial Corp. has gained 12%, compared to a 1.8% increase in the Zacks Finance sector and an 11.1% return in the Zacks Banks - Midwest industry [1]. Valuation Metrics - The stock trades at 9.3X current fiscal year EPS estimates, below the peer industry average of 10.5X, and at 12.9X on a trailing cash flow basis, compared to the peer group's average of 11.4X [6]. - The current valuation metrics suggest that the company may not be in the top tier from a value perspective [6]. Zacks Style Scores - First Financial Corp. has a Value Score of B, a Growth Score of D, and a Momentum Score of A, resulting in a combined VGM Score of B [5]. - The Zacks Style Scores provide a framework for investors to evaluate stocks based on their investment style [4]. Zacks Rank - First Financial Corp. holds a Zacks Rank of 2 (Buy), supported by rising earnings estimates, indicating potential for further stock price appreciation [7]. - The recommendation is for investors to consider stocks with Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, which applies to First Financial Corp. [7].

Company Performance - UMB Financial (UMBF) shares have increased by 8.9% over the past month, reaching a new 52-week high of $132.49 [1] - Year-to-date, UMB has gained 13.9%, outperforming the Zacks Finance sector's 1.8% gain and the Zacks Banks - Midwest industry's 11.1% return [1] Earnings and Revenue Expectations - UMB has consistently beaten earnings estimates, with an EPS of $3.08 reported on January 27, 2026, compared to a consensus estimate of $2.71 [2] - For the current fiscal year, UMB is projected to earn $12.03 per share on revenues of $2.89 billion, reflecting a 5.99% increase in EPS and a 7.96% increase in revenues [3] - The next fiscal year is expected to see earnings of $13.13 per share on revenues of $3.06 billion, indicating a year-over-year change of 9.15% in EPS and 6.04% in revenues [3] Valuation Metrics - UMB currently trades at 10.9 times the current fiscal year EPS estimates, which is above the peer industry average of 10.5 times [7] - On a trailing cash flow basis, UMB trades at 10.5 times, compared to the peer group's average of 11.4 times [7] - The stock has a PEG ratio of 0.94, which does not place it among the top tier of stocks from a value perspective [7] Zacks Rank and Style Scores - UMB holds a Zacks Rank of 1 (Strong Buy) due to a favorable earnings estimate revision trend [8] - The stock has a Value Score of B, a Growth Score of C, and a Momentum Score of A, resulting in a combined VGM Score of B [6] Industry Comparison - UMBF's performance is strong, but 1st Source Corporation (SRCE) is also a notable peer with a Zacks Rank of 2 (Buy) and a Value Score of B [9] - SRCE is expected to post earnings of $6.69 per share on revenues of $461 million for the current fiscal year, with shares gaining 9.9% over the past month [10] - The Banks - Midwest industry is positioned in the top 17% of all industries, indicating favorable conditions for both UMBF and SRCE [11]

分组1 - Acadian Asset Management reported quarterly earnings of $1.32 per share, missing the Zacks Consensus Estimate of $1.38 per share, representing an earnings surprise of -4.35% [1] - The company posted revenues of $169.7 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 17.54%, compared to year-ago revenues of $167.8 million [2] - The stock has gained approximately 11.7% since the beginning of the year, outperforming the S&P 500's gain of 0.5% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.96 on revenues of $159.29 million, and for the current fiscal year, it is $4.82 on revenues of $735.97 million [7] - The Financial - Miscellaneous Services industry, to which Acadian Asset Management belongs, is currently in the top 33% of over 250 Zacks industries, indicating a favorable outlook [8] - Acadian Asset Management has a Zacks Rank of 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6]

Core Insights - AstraZeneca (AZN) is set to report its fourth-quarter and full-year 2025 results on February 10, with a consensus estimate for quarterly sales at $15.71 billion and earnings at $2.18 per share [1][8] Group 1: Sales Drivers - Key medicines, particularly cancer drugs Calquence, Lynparza, Tagrisso, and Imfinzi, along with diabetes medication Farxiga/Forxiga, are expected to significantly contribute to fourth-quarter sales, driven by strong demand [2][8] - The Zacks Consensus Estimates for the key drugs are as follows: Calquence at $916 million, Lynparza at $881 million, Tagrisso at $1.88 billion, Imfinzi at $1.67 billion, and Farxiga/Forxiga at $2.01 billion [2] Group 2: Additional Contributions - Other drugs, including asthma medication Fasenra, COPD treatment Breztri, and lupus drug Saphnelo, are also anticipated to support sales growth, with estimates for Symbicort and Fasenra at $696 million and $544 million, respectively [4] - Sales from AstraZeneca's Rare Disease drugs, particularly Ultomiris and Strensiq, have shown significant growth and are expected to continue this trend in the upcoming quarter [5] Group 3: Financial Performance and Costs - The company is expected to see a rise in core operating costs due to investments in recent product launches and increased expenses for new clinical studies [6] - AstraZeneca has a history of decent performance, beating earnings estimates in three of the last four quarters, with an average surprise of 3.81% [7] Group 4: Earnings Prediction - The current Earnings ESP for AstraZeneca stands at -4.59%, indicating that an earnings beat is not predicted this time [10][11] - The Most Accurate Estimate for earnings is $2.08 per share, while the Zacks Consensus Estimate remains at $2.18 [11]

Core Insights - Hasbro, Inc. (HAS) is set to report its fourth-quarter fiscal 2025 results on February 10, with expectations of earnings and revenues rising year over year [1][8] Earnings Estimates - The Zacks Consensus Estimate for earnings is 99 cents per share, reflecting a 115.2% increase from 46 cents reported a year ago [2] - Revenue estimates stand at $1.29 billion, indicating a 16.8% increase from the prior year's quarter [2] Factors Influencing Q4 Performance - The Wizards of the Coast segment, particularly MAGIC: The Gathering, is expected to have driven top-line performance, with strong demand during the holiday season supported by major releases [3] - Consumer Products are anticipated to have contributed significantly to revenues, aided by improved shipment flow and retailer restocking following earlier disruptions [4] - Pricing strategies and product mix, with many items priced under $20, helped sustain consumer demand without aggressive price increases [5] Revenue Predictions - Total Consumer Products revenues are projected to decline by 4% year over year to $716.2 million, while Wizards of the Coast & Digital Gaming revenues are expected to rise by 53.4% year over year to $520.2 million [6] Earnings Performance Drivers - Earnings growth is likely supported by operating leverage from higher revenues in the Wizards segment, particularly from MAGIC, which has high margins [7] - Incremental holiday sales are expected to flow efficiently through the income statement, aided by consistent royalty expenses and improved shipment leverage in Consumer Products [7] Earnings Beat Expectations - The model predicts an earnings beat for Hasbro, with an Earnings ESP of +16.50% and a Zacks Rank of 3 (Hold) [9]

Core Viewpoint - Masco Corporation (MAS) is expected to report its fourth-quarter 2025 results on February 10, with anticipated declines in both adjusted earnings and net sales compared to the previous year [1][2]. Financial Performance - In the last reported quarter, Masco's adjusted earnings and net sales missed the Zacks Consensus Estimate by 4.9% and 1.1%, respectively, with year-over-year declines of 3% in net sales and 10% in earnings [1]. - The Zacks Consensus Estimate for adjusted EPS remains unchanged at 78 cents, reflecting a 12.4% decline from the year-ago EPS of 89 cents [2]. Sales Trends - The fourth-quarter top line is expected to decline year over year, primarily due to reduced contributions from the Decorative Architectural Products segment, which accounted for 35% of total net sales in Q3 2025 [3]. - The Plumbing Products segment, which represented 65% of total net sales in Q3 2025, is anticipated to support the top line with a projected 2.3% increase in net sales to $1.22 billion, despite challenges in other segments [5][6]. Geographic Performance - North American net sales, which accounted for 78.9% of total net sales in Q3 2025, are expected to decline by 1.9% year over year to $1.42 billion, while international sales are projected to increase by 3.3% to $391.6 million [7]. Margin Analysis - The company's bottom line is likely to decline year over year due to higher costs from tariffs and commodity inflation, with pressures from elevated import duties and increased material costs [9]. - Adjusted operating margins for Plumbing Products and Decorative Architectural Products are expected to decline by 100 basis points to 15.8% and by 300 basis points to 14.7%, respectively [11]. Earnings Prediction - The model does not predict an earnings beat for Masco this quarter, with an Earnings ESP of -3.33% and a Zacks Rank of 4 (Sell) [12].